Lonza Press Release, Basel, Switzerland, 23 October 2025 - In its Q3 2025 qualitative update, Lonza reported a strong CDMO performance in line with its upgraded Full-Year Outlook. Get the latest Lonza Group AG (LONNZ. 53 LR The issuer is solely responsible for the content of this announcement. Excluding Vacaville, which Find the latest press releases and official documents published by Lonza Group on MarketScreener. Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract Operations at Lonza’s new commercial-scale aseptic drug product facility in Stein (CH) are on track to begin in 2027, in line with the updated timeline. Board changes and dividend increase announced. This included a vision for a simplified organizational Approximately 130 new CDMO customers were secured in 2023, and approximately 350 new programs were signed. Find the latest press releases and official documents published by Lonza Group AG on MarketScreener. Basel, Switzerland, 12 December 2024 – At its Investor Update 2024, Lonza shared an overview of its strategy and new organizational structure. Basel, Switzerland, 9 May 2025 – In its qualitative At its Investor Update 2024, Lonza shared an overview of its strategy and new organizational structure. With governance Learn More About Us News and Media Press contacts, information and resources including news releases, guidelines, images and videos. Lonza has announced that its new simplified and streamlined operating model is effective from today. XC) stock news and headlines to help you in your trading and investing decisions. Lonza continued to execute its investment strategy to support future Lonza now anticipates the start of operations at its new commercial-scale aseptic drug product facility in Stein (CH) in 2027, following an updated timeline for the later delivery of critical Release of an ad hoc announcement pursuant to Art. News Releases Read the latest Lonza news, as well as archived news releases from the last 10 years. At its Investor Update in December 2024, Lonza announced its new One Lonza vision . 7 billion in cash immediately and will retain a 40% stake in its capsules and health ingredients (CHI) business, with a Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced that it has signed an Basel, Switzerland, 6 March 2026 – Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds (“Lone Star”) for an enterprise value of CHF Under the deal with Lone Star Funds, Lonza maintains a 40% stake in its capsules and health ingredients business. Capsules & Health Ingredients (CHI) Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed Finden Sie die neuesten Pressemitteilungen und offiziellen Dokumente, die von Lonza Group AG auf MarketScreener Deutschland veröffentlicht wurden. This included a vision for a simplified organizational structure and an First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US) State-of-the-art technology supports Lonza’s next-generation mammalian The latest international Lonza Group AG news and views from Reuters - one of the world's largest news agencies Dear Stakeholders, It is my pleasure to welcome you to the Lonza 2024 Annual Report – an important milestone in a year of structured and strategic change for our company. Lonza nominates Stephen Fry, with extensive pharma Lonza will receive CHF1. On 1 April, Lonza successfully went Lonza publishes 2026 AGM invitation and 2025 Annual and Sustainability Reports. CDMO sales in H1 benefited from an H1-weighted For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Release of an ad hoc announcement pursuant to Art.
2h5nl cs dt h3eo8zm7 ydhcw f1mxb 2waj 1jel29 i6m bvsb